Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists

被引：17
|
作者：
Mann, Johannes F. E. [1 ,2 ]
Muskiet, Marcel H. A. [3 ]
机构：
[1] KfH Kidney Ctr, 15 Isoldenst, D-80804 Munich, Germany
[2] Friedrich Alexander Univ, Univ Hosp, Dept Nephrol & Hypertens, Erlangen, Germany
[3] Vrije Univ, Amsterdam Univ, Med Ctr, Dept Internal Med,Diabet Ctr, Amsterdam, Netherlands
来源：
KIDNEY INTERNATIONAL | 2021年 / 99卷 / 02期
关键词：
RENAL OUTCOMES; CARDIOVASCULAR OUTCOMES; LIRAGLUTIDE;
D O I：
10.1016/j.kint.2020.08.036
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：314 / 318
页数：5
相关论文
共 50 条
  • [1] Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes
    Farngren, Johan
    Ahren, Bo
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 99 : 25 - 31
  • [2] GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes
    Ahrén, B
    Schmitz, O
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 867 - 876
  • [3] Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?
    Davies, Melanie J.
    Bianchi, Cristina
    Del Prato, Stefano
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 107
  • [4] SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
    El Mouhayyar, Christopher
    Riachy, Ruba
    Khalil, Abir Bou
    Eid, Asaad
    Azar, Sami
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2020, 2020
  • [5] Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
    Zeqing Zhang
    Xi Chen
    Puhan Lu
    Jianhua Zhang
    Yongping Xu
    Wentao He
    Mengni Li
    Shujun Zhang
    Jing Jia
    Shiying Shao
    Junhui Xie
    Yan Yang
    Xuefeng Yu
    Cardiovascular Diabetology, 16
  • [6] Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
    Zhang, Zeqing
    Chen, Xi
    Lu, Puhan
    Zhang, Jianhua
    Xu, Yongping
    He, Wentao
    Li, Mengni
    Zhang, Shujun
    Jia, Jing
    Shao, Shiying
    Xie, Junhui
    Yang, Yan
    Yu, Xuefeng
    CARDIOVASCULAR DIABETOLOGY, 2017, 16
  • [7] The Pharmacologic Basis for Clinical Differences Among GLP-1 Receptor Agonists and DPP-4 Inhibitors
    Morales, Javier
    POSTGRADUATE MEDICINE, 2011, 123 (06) : 189 - 201
  • [8] Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
    Neumiller, Joshua J.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2009, 49 : S16 - S29
  • [9] GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease
    Neumiller, Joshua J.
    Alicic, Radica Z.
    Tuttle, Katherine R.
    KIDNEY AND DIALYSIS, 2022, 2 (03): : 386 - 398
  • [10] Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
    Lin, Donna Shu-Han
    Lee, Jen-Kuang
    Chen, Wen-Jone
    DIABETOLOGIA, 2021, 64 (09) : 1949 - 1962
12345